4647 |
CHIP/Complex PCI in 2018: Practical, Operational, and Logistical Aspects |
David E. Kandzari |
Apr. 28. 18 |
4646 |
Is In-Stent Restenosis a Benign Event? |
Tullio Palmerini |
Apr. 28. 18 |
4645 |
Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment |
Alan C. Yeung |
Apr. 28. 18 |
4644 |
Future DES Platforms: New Drugs, Polymers, and Metals |
David E. Kandzari |
Apr. 28. 18 |
4643 |
Can Improved Scaffold Technology Reduce Clinical Complications?: Insights and Speculation |
Patrick W. Serruys |
Apr. 28. 18 |
4642 |
Bioresorbable Scaffolds: Rethinking All Mechanism of Scaffold Thrombosis and How to Fix It? |
Yoshinobu Onuma |
Apr. 28. 18 |
4641 |
Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement? |
Barry D. Rutherford |
Apr. 28. 18 |
4640 |
The Lesson from DECISION-CTO Trial |
Seung-Jung Park |
Apr. 28. 18 |
4639 |
The Lesson from EURO CTO Trial |
Gerald Werner |
Apr. 28. 18 |
4638 |
ISR CTO: What Is the Difference from De Novo CTO? |
Kenya Nasu |
Apr. 28. 18 |